Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $2.41 · Revenue $231.79M · 5 analysts
Est. EPS $0.31 · Revenue $78.06M · 5 analysts
Est. EPS $1.46 · Revenue $312.10M · 6 analysts
Est. EPS $0.29 · Revenue $92.77M · 3 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $106.0M | +38.9% | +90.6% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-81.1M | +33.9% | -1.9% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +100.0% | 0.0% | +648.5% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -87.3% | +51.4% | +53.0% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -76.6% | +52.4% | +46.5% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-34.5M | +69.5% | +30.1% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -32.6% | +78.0% | +63.3% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 6.8% | +24.5% | +3108.6% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 5.52x | +62.1% | -41.6% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $346.5M | -25.2% | -17.0% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.08 vs -0.95 | -13.5% | -0.62 vs -0.57 | -7.9% |
| Revenue Surprise | $106.0M vs $122.8M | -13.7% | $4.6M vs $4.5M | +1.2% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jul 6, 2026 | Hollywood Mark | officer: EVP & Chief Operating Officer | Common Stock | A | 939 | $22.22 |
| May 13, 2026 | Schneider Paul R | officer: EVP, General Counsel | Stock Option (Right to Buy) | A | 178,000 | $24.57 |
| May 13, 2026 | Schneider Paul R | officer: EVP, General Counsel | Restricted Stock Unit | A | 119,000 | — |
| May 13, 2026 | Schneider Paul R | officer: EVP, General Counsel | No securities are beneficially owned | — | 0 | — |
| Apr 9, 2026 | Schayowitz Adam | officer: See Remarks | Performance Stock Unit | A | 76,000 | — |
Operator: Good day, and thank you for standing by. Welcome to Zymeworks First Quarter 2026 Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Shrinal Inamdar, VP of Investor Relations. Your line is open. Shrinal Inamdar: Thank you, operator. Good afternoon, everyone, and thank you for joining our first quarter 2026 results conference call. As usual, I'd like to remind you that we'll be making a number of forward-looking statements during this call, including, without limitation, those forward-looking statements identified in our slides and the accompanying oral commentary. These forward-looking statements are based upon our current expectations and various assumptions and are subject to the risks and uncertainties, including those associated with companies in our industry and at our stage of development. For a discussion of these risks and uncertainties, we refer you to our latest SEC filings as found on our website and as filed with the SEC. In a moment, I'll hand over the call to Ken Galbraith, our Chair and CEO, who will provide an overview of recent business updates. Ken will then hand the call over to Kristin Stafford, our Chief Financial Officer, to discuss our cash position and financial results for the first quarter 2026. Dr. Paul Moore will then provide a brief summary of new preclinical data disclosed at AACR on our pan-RAF ADCs. And following this, Dr. Sabeen Mekan, our SVP and Chief Medical Officer, will provide progress updates on both the Phase I clinical trial of ZW191 and ZW251. At the end of the call, Ken, Kristen, Sabine and Paul will be joined for a Q&A session with Scott Pashon, our Chief Business Officer; and Adam Chherowitz, Head of R&D. As a reminder, the audio and slides from this call will also be available on Zymeworks website later today. I'll now hand the call over to Ken. Kenneth Galbraith: Thank you, Sal, and good afternoon, everyone. We're pleased to be reporting on further progress this quarter on both our wholly owned and partnered assets. The PDUFA date of August 25, 2026, for zanidatamab and first-line GEA in the U.S., together with the completion of an sBLA filing in China for first-line GEA marks an important inflection point and near-term foundational value-driving opportunity for Zymeworks. These regulatory milestones provide increasing visibility towards commercialization in first-line HER2-positive GEA and accompany continued clinical development in additional settings such as breast cancer, helping to establish a clear baseline for zanidatamab's value. If you didn't get a chance to tune in, we'd urge you to listen into Jazz's disclosures within their earnings call earlier this week on preparedness and launch activities for GEA in anticipation of an FDA approval later this year on or before the PDUFA date. With our partners, Jazz and B1, bringing established commercial …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Kenneth H. Galbraith | Chairman of the Board, Chief Executive Officer & President | USD 1,708,375 | Male | 1962 | Active |
Paul Moore | Chief Scientific Officer | USD 998,368 | — | 1967 | Active |
Thomas Spreter Von Kreudenstein | Director of Protein Engineering | — | — | — | Active |
Lindsey Foulkes | Senior Vice President of Corporate Development & Strategy | — | — | — | Active |
Adam Schayowitz | Executive VP and Head of Research & Development | — | — | — | Active |
Alexey Berezhnoy | Director of Immunology | — | — | — | Active |
Ryan Dercho | Senior Director of Corporate Affairs | — | — | — | Active |
Shrinal Inamdar | Vice President of Investor Relations | — | Female | — | Active |
Nina Weisser | Director of Multispecific Antibody Therapeutics | — | — | — | Active |
Mark Hollywood | Executive VP & Chief Operating Officer | — | Male | 1969 | Active |
Paul R. Schneider | Executive VP & General Counsel | — | Male | 1971 | Active |
Laura O'Connor | Senior VP & Chief Human Resources Officer | — | Female | — | Active |
Scott Platshon | Executive VP & Chief Business Officer | — | Male | 1991 | Active |
Diana Papove | Vice President of Corporate Communications | — | Female | — | Active |
Kristin Stafford | Executive VP & CFO | — | Female | 1982 | Active |
Bijal Desai | Senior Vice President of Finance | — | Female | — | Active |
VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2026 financial results after market close on August 6, 2026.
Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cash-flow platform anchored by Yupelri. ZYME gains durable, growing cash flows—$60M annually from Yupelri—with patent protection to 2039, supporting internal R&D and reducing reliance on equity issuance. The acquisition's innovative financing structure ringfences risk, offers immediate accretion, and diversifies revenue beyond oncology, enhancing earnings visibility.
TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.
Zymeworks Inc. (ZYME) M&A Call Transcript
Zymeworks Inc. (NASDAQ:ZYME) said Monday it has agreed to acquire Theravance Biopharma Inc. (NASDAQ:TBPH) in an all-cash transaction valued at about $929 million.
